{
    "title": "A bill to amend the Public Health Service Act to provide protections for first responders.",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Bioterror and Pandemic Preparedness \nProtection Act''.\n\nSEC. 2. LIABILITY PROTECTIONS FOR PANDEMICS, EPIDEMICS, AND \n              COUNTERMEASURES.\n\n    Part B of title III of the Public Health Service Act is amended by \ninserting after section 319F-2 (42 U.S.C. 247d-6b) the following:\n\n``SEC. 319A-3. LIABILITY PROTECTIONS FOR PANDEMICS, EPIDEMICS, AND \n              SECURITY COUNTERMEASURES.\n\n    ``(a) Authority.--The Secretary shall be solely and exclusively \nresponsible for the administration of this section. This section shall \napply with respect to the design, development, clinical testing and \ninvestigation, manufacture, labeling, distribution, sale, purchase, \ndonation, dispensing, administration, or use of a security \ncountermeasure or a qualified pandemic or epidemic product.\n    ``(b) Litigation Management.--\n            ``(1) Federal cause of action.--\n                    ``(A) In general.--There shall exist an exclusive \n                Federal cause of action for all claims arising out of, \n                relating to, or resulting from the design, development, \n                clinical testing and investigation, manufacture, \n                labeling, distribution, sale, purchase, donation, \n                dispensing, administration, and use of a qualified \n                pandemic or epidemic product or a security \n                countermeasure as provided for in clauses (i) and (ii) \n                of paragraph (2)(B).\n                    ``(B) Action.--With respect to the Federal cause of \n                action provided in subparagraph (A)--\n                            ``(i) an action may be commenced solely and \n                        exclusively against the United States for \n                        claims identified in subparagraph (A) that are \n                        against a manufacturer, distributor, or health \n                        care provider;\n                            ``(ii) no cause of action shall be \n                        maintained against a manufacturer, distributor, \n                        or health care provider for claims identified \n                        in subparagraph (A); and\n                            ``(iii) for products subject to designation \n                        by the Secretary as provided for in clause (ii) \n                        of paragraph (2)(B), the protections set forth \n                        in clauses (i) and (ii) shall apply to all \n                        claims identified in subparagraph (A) that \n                        involve products sold, purchased, donated, \n                        dispensed, or administered during the effective \n                        period set forth in the designation provided \n                        for in paragraph (2)(F), regardless of the date \n                        of alleged injury.\n                    ``(C) Jurisdiction.--The United States District \n                Court for the District of Columbia shall have sole and \n                exclusive jurisdiction over any claim for loss of \n                property, personal injury, or death arising out of, \n                relating to, or resulting from the design, development, \n                clinical testing and investigation, manufacture, \n                labeling, distribution, sale, purchase, donation, \n                dispensing, administration, or use of a qualified \n                pandemic or epidemic product or security countermeasure \n                as provided for in clauses (i) and (ii) of paragraph \n                (2)(B).\n            ``(2) Affirmative defense.--\n                    ``(A) In general.--There shall be a rebuttable \n                presumption that the Federal Government is immune from \n                liability in an action described in subparagraph (B).\n                    ``(B) Action described.--An action described in \n                this subparagraph is an action that is commenced \n                against the United States for claims arising out of, \n                relating to, or resulting from the design, development, \n                clinical testing and investigation, manufacture, \n                labeling, distribution, sale, purchase, donation, \n                dispensing, administration, or use of--\n                            ``(i) a security countermeasure that has \n                        been procured for the National Strategic \n                        Stockpile under section 319F-2 or a qualified \n                        pandemic or epidemic product that has been \n                        procured by the Secretary; or\n                            ``(ii) a security countermeasure or \n                        qualified pandemic or epidemic product in \n                        anticipation of and preparation for, in defense \n                        against, or in response or recovery to an \n                        actual or potential public health emergency, \n                        that is a security countermeasure or is \n                        designated as a qualified pandemic or epidemic \n                        product by the Secretary after the Secretary \n                        declared a public health emergency as described \n                        in paragraph (1) or (2) of section 319(a).\n                    ``(C) Rebuttability.--\n                            ``(i) In general.--The presumption \n                        described in subparagraph (A) shall be overcome \n                        by a determination by the Secretary as provided \n                        for in subparagraph (D).\n                            ``(ii) Investigation by secretary.--A party \n                        seeking a determination under subparagraph (D) \n                        may petition the Secretary to investigate \n                        claims against a manufacturer, distributor, \n                        dispenser, or health care provider arising out \n                        of, relating to, or resulting from the design, \n                        development, clinical testing and \n                        investigation, manufacture, labeling, \n                        distribution, sale, purchase, donation, \n                        dispensing, administration, or use of products \n                        as provided for in clauses (i) and (ii) of \n                        subparagraph (B). The decision to undertake \n                        such investigation shall be within the \n                        Secretary's discretion and shall not be subject \n                        to judicial review.\n                    ``(D) Determination by secretary.--\n                            ``(i) In general.--In making a \n                        determination under this subparagraph, the \n                        Secretary must find clear and convincing \n                        evidence that the manufacturer, distributor, or \n                        health care provider intentionally or with \n                        willful disregard violated a provision of the \n                        Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n                        301 et seq.) or this Act and such violation--\n                                    ``(I) caused the product to present \n                                a significant risk to health; and\n                                    ``(II) proximately caused the \n                                injury alleged by the petitioner.\n                            ``(ii) Notice and hearing.--Prior to the \n                        Secretary's making a determination under clause \n                        (i), the manufacturer, distributor, dispenser, \n                        or health care provider shall have notice and a \n                        right to a formal hearing in accordance with \n                        section 556 of title 5, United States Code.\n                            ``(iii) Judicial review.--At any time prior \n                        to the 90th day following a determination by \n                        the Secretary under clause (i) of this \n                        subparagraph, any manufacturer, distributor, or \n                        health care provider who will be adversely \n                        affected by such determination may file a \n                        petition with the United States Court of \n                        Appeals for the circuit wherein such person \n                        resides or has his principal place of business, \n                        for a judicial review of such determination. A \n                        copy of the petition shall be forthwith \n                        transmitted by the clerk of the court to the \n                        Secretary or other officer designated by the \n                        Secretary for that purpose. The Secretary \n                        thereupon shall file in the court the record of \n                        the findings on which the Secretary based his \n                        or her determination. The filing of a petition \n                        under this clause shall automatically stay the \n                        Secretary's determination for the duration of \n                        the judicial proceeding. The sole parties to \n                        the judicial proceeding shall be the Secretary \n                        and the petitioner. Intervention by third \n                        parties in the judicial proceeding shall not be \n                        permitted. No subpoenas shall be issued nor \n                        shall other compulsory process apply. The \n                        court's review of a determination by the \n                        Secretary under this clause shall conform to \n                        the procedures for judicial review of \n                        administrative orders set forth in paragraphs \n                        (2) through (6) of section 371(f) of title 21, \n                        United States Code, to the extent consistent \n                        with this section.\n                    ``(E) Scope.--The presumption under subparagraph \n                (A) shall apply regardless of whether the claim against \n                the United States arises from the design, development, \n                clinical testing and investigation, manufacture, \n                labeling, distribution, sale, purchase, donation, \n                dispensing, administration, or use by the Federal \n                Government or by non-Federal Government customers.\n                    ``(F) Designation.--In any declaration of a public \n                health emergency under section 319, the Secretary shall \n                identify the pandemic, epidemic, or biological, \n                chemical, nuclear agent, or toxin that presents, or may \n                present, a public health emergency and shall designate \n                the security countermeasure(s) or qualified pandemic or \n                epidemic product(s) to be sold by, purchased from, or \n                donated by a manufacturer or drawn from the National \n                Strategic Stockpile and shall specify in such \n                designation the beginning and ending dates of such \n                sale, purchase, donation, or use from the stockpile. \n                The period so defined shall be the effective period of \n                such qualification for any products specified in the \n                designation. The declaration shall subsequently be \n                amended to reflect any additional sale, purchase, or \n                donation of products specified in the designation.\n    ``(c) Definitions.--In this section:\n            ``(1) Health care provider.--The term `health care \n        provider' means a person, including a volunteer, who lawfully \n        prescribes, administers, dispenses, or provides a facility to \n        administer a security countermeasure or a qualified pandemic or \n        epidemic product, including persons who prescribe, administer, \n        or provide a facility to administer in accordance with a \n        designation under subsection (b)(2)(F).\n            ``(2) Loss.--The term `loss' means death, bodily injury, or \n        loss of or damage to property, including business interruption \n        loss.\n            ``(3) Non-federal government customers.--The term `non-\n        Federal Government customers' means any customer of a \n        manufacturer that is not an agency or instrumentality for the \n        United States Government with authority under Public Law 85-804 \n        to provide for indemnification under certain circumstances for \n        third-party claims against its contractors, including a State, \n        a local authority, a private entity, a health care provider, or \n        an individual.\n            ``(4) Qualified pandemic or epidemic product.--The term \n        `qualified pandemic or epidemic product' means a drug (as such \n        term is defined in section 201(g)(1) of the Federal Food, Drug, \n        and Cosmetic Act (21 U.S.C. 321(g)(1))), biological product (as \n        such term is defined by section 351(i) of this Act) or device \n        (as such term is defined by section 201(h) of the Federal food, \n        Drug and Cosmetic Act (21 U.S.C. 321(h))) designed, developed, \n        modified, or procured to diagnose, mitigate, prevent, treat, or \n        cure a pandemic or epidemic or limit the harm such pandemic or \n        epidemic might otherwise cause or a serious or life-threatening \n        disease or condition caused by such a product, that--\n                    ``(A) is approved or cleared under chapter V of the \n                Federal Food, Drug, and Cosmetic Act or licensed under \n                section 351 of this Act;\n                    ``(B) is a product for which the Secretary \n                determines that sufficient and satisfactory clinical \n                experience or research data (including data, if \n                available, from pre-clinical and clinical trials) \n                support a reasonable conclusion that the countermeasure \n                will qualify for approval or licensing within 8 years \n                after the date the Secretary declares a public health \n                emergency as described in paragraph (1) or (2) of \n                section 319(a); or\n                    ``(C) is authorized by the Secretary under this \n                section, except that the Secretary may authorize under \n                this section the emergency use of a product only if, \n                after consultation with the Director of the National \n                Institutes of Health and the Director of the Centers \n                for Disease Control and Prevention (to the extent \n                feasible and appropriate given the circumstances of the \n                emergency involved), the Secretary concludes--\n                            ``(i) that an agent or toxin identified in \n                        a declaration described under subsection (b) \n                        can cause a serious or life-threatening disease \n                        or condition;\n                            ``(ii) that, based on the totality of the \n                        scientific evidence available to the Secretary, \n                        including data from adequate and well-\n                        controlled clinical trials, if available, it is \n                        reasonable to believe that--\n                                    ``(I) the product may be effective \n                                in diagnosing, mitigating, preventing, \n                                treating or curing--\n                                            ``(aa) a pandemic or \n                                        epidemic; or\n                                            ``(bb) a serious or life-\n                                        threatening disease or \n                                        condition caused by a product; \n                                        and\n                                    ``(II) the known and potential \n                                benefits of the product, when used to \n                                diagnose, mitigate, prevent, treat or \n                                cure such disease or condition, \n                                outweigh the known and potential risks \n                                of the product;\n                            ``(iii) that there is no adequate, \n                        approved, and available alternative to the \n                        product for diagnosing, mitigating, preventing, \n                        treating or curing such disease or condition; \n                        and\n                            ``(iv) that such other criteria as the \n                        Secretary may by regulation prescribe are \n                        satisfied.\n            ``(5) Security countermeasure.--The term `security \n        countermeasure' has the meaning given such term in section \n        319F-2(c)(1)(B).''.\n\nSEC. 3. TECHNICAL AMENDMENT.\n\n    Section 319(a)(1) of the Public Health Service Act (42 U.S.C. 247d \n(a)(1)) is amended by inserting ``, or may present,'' after \n``present''."
}